全文获取类型
收费全文 | 10774篇 |
免费 | 561篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 159篇 |
儿科学 | 302篇 |
妇产科学 | 288篇 |
基础医学 | 1293篇 |
口腔科学 | 237篇 |
临床医学 | 595篇 |
内科学 | 3008篇 |
皮肤病学 | 344篇 |
神经病学 | 751篇 |
特种医学 | 176篇 |
外科学 | 1570篇 |
综合类 | 113篇 |
一般理论 | 1篇 |
预防医学 | 1062篇 |
眼科学 | 223篇 |
药学 | 669篇 |
中国医学 | 65篇 |
肿瘤学 | 504篇 |
出版年
2023年 | 73篇 |
2022年 | 43篇 |
2021年 | 241篇 |
2020年 | 120篇 |
2019年 | 311篇 |
2018年 | 479篇 |
2017年 | 246篇 |
2016年 | 267篇 |
2015年 | 239篇 |
2014年 | 296篇 |
2013年 | 410篇 |
2012年 | 681篇 |
2011年 | 767篇 |
2010年 | 400篇 |
2009年 | 262篇 |
2008年 | 637篇 |
2007年 | 641篇 |
2006年 | 714篇 |
2005年 | 661篇 |
2004年 | 605篇 |
2003年 | 570篇 |
2002年 | 517篇 |
2001年 | 367篇 |
2000年 | 448篇 |
1999年 | 318篇 |
1998年 | 49篇 |
1997年 | 39篇 |
1996年 | 26篇 |
1995年 | 19篇 |
1994年 | 23篇 |
1993年 | 24篇 |
1992年 | 102篇 |
1991年 | 87篇 |
1990年 | 96篇 |
1989年 | 65篇 |
1988年 | 55篇 |
1987年 | 60篇 |
1986年 | 61篇 |
1985年 | 46篇 |
1984年 | 26篇 |
1983年 | 24篇 |
1979年 | 14篇 |
1978年 | 15篇 |
1976年 | 14篇 |
1974年 | 13篇 |
1973年 | 16篇 |
1971年 | 22篇 |
1970年 | 16篇 |
1969年 | 19篇 |
1967年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
131.
132.
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. 总被引:3,自引:0,他引:3
Silvia Hernández Elena López-Knowles Josep Lloreta Manolis Kogevinas Roberto Jaramillo Alex Amorós Adonina Tardón Reina García-Closas Consol Serra Alfredo Carrato Núria Malats Francisco X Real 《Clinical cancer research》2005,11(15):5444-5450
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer. FGFR3 mutations are associated with low-grade tumors and a favorable prognosis. Tp53 alterations are associated with advanced tumors and, possibly, with a poor prognosis. We focus here on the subgroup of T1G3 superficial tumors because they are a major clinical challenge. Patients (n = 119) were identified from a prospective study of 1,356 cases. Mutations in FGFR3 (exons 7, 10, and 15) and Tp53 (exons 4-9) were analyzed using PCR and direct sequencing. All cases were followed for recurrence and death. Survival was analyzed using Kaplan-Meier curves and multivariable Cox regression. FGFR3 mutations were detected in 20 (16.8%) tumors; 100 mutations in Tp53 were found in tumors from 78 (65.5%) cases. Multiple alterations in Tp53 were present in 19 tumors (16%). Inactivating mutations were present in 58% of tumors. The combined mutation distribution (FGFR3/Tp53) was: wt/wt (34.5%), mut/wt (7.6%), wt/mut (48.7%), and mut/mut (9.2%), indicating that the presence of either mutation did not depend on the other (P value = 0.767). FGFR3 and Tp53 mutations were not associated with clinicopathologic characteristics of patients and did not predict, alone or in combination, recurrence or survival. Taking the risk of the wt/wt group as reference, the mutation-associated risks of cancer-specific mortality were: mut/wt 1.42 (0.15-13.75), wt/mut 0.67 (0.19-2.31), mut/mut 1.62 (0.27-9.59). These molecular features support the notion that T1G3 tumors are at the crossroads of the two main molecular pathways proposed for bladder cancer development and progression. 相似文献
133.
134.
135.
Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention 总被引:2,自引:0,他引:2
Juan F. Ascaso Arturo Fernández-Cruz Pedro González Santos Antonio Hernández Mijares Alipio Mangas Rojas Prof. Jesus Millán Luis Felipe Pallardo Juan Pedro-Botet Francisco Pérez-Jiménez Gonzalo Pía Xavier Pintó Ignacio Plaza Juan Rubiés-Prat 《Am J Cardiovasc Drugs》2004,4(5):299-314
In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (<100 mg/dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. 相似文献
136.
Luz A. López-Ramírez Nahúm V. Hernández Nancy E. Lozoya-Pérez Leila M. Lopes-Bezerra Héctor M. Mora-Montes 《Research in microbiology》2018,169(3):188-197
Sporothrix schenckii is one of the causative agents of the deep-seated mycosis sporotrichosis, a fungal infection with worldwide distribution. Fungus-specific molecules and biosynthetic pathways are potential targets for the development of new antifungal drugs. The MNT1/KRE2 gene family is a group of genes that encode fungus-specific Golgi-resident mannosyltransferases that participate in the synthesis of O-linked and N-linked glycans. While this family is composed of five and nine members in Candida albicans and Saccharomyces cerevisiae, respectively, the S. schenckii genome contains only three putative members. MNT1 has been previously characterized as an enzyme that participates in the synthesis of both N-linked and O-linked glycans. Here, we aimed to establish the functional role of the two remaining family members, KTR4 and KTR5, in the protein glycosylation pathways by using heterologous complementation in C. albicans mutants lacking genes of the MNT1/KRE2 family. The two S. schenckii genes restored defects in the elaboration of N-linked glycans, but no complementation of mutants that synthesize truncated O-linked glycans was observed. Therefore, our results suggest that MNT1 is the sole member with a role in O-linked glycan elaboration, whereas the three family members have redundant activity in the S. schenckii N-linked glycan synthesis. 相似文献
137.
138.
Armando Pérez-Rangel José Manuel Hernández Araceli Castillo-Romero Lilián Yépez-Mulia Rafael Castillo Francisco Hernández-Luis Benjamín Nogueda-Torres Juan Pedro Luna-Arias Gerardo Radilla Gloria León-Avila 《Parasitology research》2013,112(9):3251-3257
In the present study, we evaluated the effect of an albendazole (ABZ) derivative JVG9 on cultured Giardia intestinalis. To assess the JVG9 effects, we evaluated the tubulin cytoskeleton by confocal microscopy, and we found that the characteristic staining was modified. The scanning electron microscopy images revealed extremely damaged trophozoites and cyst-like cells. The confocal images revealed that this drug triggered the expression of cyst wall protein 1 and encystation. We also found that at low doses, AL triggered the encystation process too. 相似文献
139.
M.C. Serrano Vicente H. Navarro Aznárez P. Carrera Lasfuentes M.R. Abad Sazatornil O. Horna Oreja M.J. Rabanaque Hernández 《Farmacia hospitalaria》2012,36(4):187-193
IntroductionThe treatment used after failure of at least two lines of antiretroviral treatment in HIV patients is called salvage therapy. The study aims to describe the characteristics of HIV patients subjected to such a regimen, and determine the safety and effectiveness of treatment with tipranavir (TPV), darunavir (DRV), enfuvirtide (ENF) and etravirine (ETR) combined with an optimised antiretroviral regimen.Patients and methodsHIV patients treated with ENF, TPV, DRV or ETR in a tertiary hospital infectious diseases department subjected to at least 12 weeks treatment. The patient characteristics are described and the effectiveness, durability and adherence to the treatment analysed.ResultsThere were 28 patients studied, with an average of 10 treatment regimens prior to starting salvage therapy (SD = 3.5; 95 % CI, 8.9-11.1). A total of 85.7 % patients had treatment adherence > 90 %. For ENF, 70.8 % of the treatment lines were suspended during follow-up. After salvage therapy, the percentage of patients with viral load (VL) < 400 copies/ml doubled, and cases with undetectable CV (< 50 copies/ml) almost tripled. The treatments used did not change the liver or kidney profiles; however, they changed the lipid profile and increased the percentage of patients with hyperglycaemia.ConclusionsThe salvage therapy studied was effective. Good adherence to the therapy is critical for its effectiveness. 相似文献
140.